Trump considering Gottlieb to head FDA

Dr Scott Gottlieb, a partner at one of the world's largest venture capital funds and a former deputy commissioner at the US Food and Drug Administration, is being considered by President-elect Donald Trump to run the agency, according to sources close to the transition team.

Gottlieb, 44, a venture partner at New Enterprise Associates and resident fellow at the American Enterprise Institute, a conservative think tank based in Washington, is well known in health policy circles and is a frequent commentator on television and in print.

Gottlieb is being considered alongside Jim O'Neill, a self-declared libertarian and colleague of Peter Thiel, the co-founder of Mithril Capital Management who was an early Trump supporter and is now advising his transition team. Bloomberg News first reported that Trump was looking at O'Neill.

Michael Gaba, federal policy leader of law firm Holland & Knight's national Healthcare & Life Sciences Team, said Gottlieb would be more palatable to more people than O'Neill, who believes drugs should be allowed on the market before their efficacy has been established, as long as they are safe.

Even the drug industry would likely oppose that stance, Gaba said, since companies want to be able to make credible claims that their products are effective in treating the diseases they say do.

"They want the FDA's Good Housekeeping seal of approval," Gaba said last week, adding, however, that drug makers would like to provide less data to get it.

Gottlieb would be a more traditional choice than O'Neill and fits the profile of what Trump's administration seems to be looking for, he said.